SELLAS Life Sciences SLS
NASDAQ SLS
$11.97 +0.46 (+4.00%)
As of: Sep 30, 2026 · 11:37 AM EDT

SELLAS Life Sciences (SLS) Receivables - Accured (2017)

Updated

SELLAS Life Sciences (SLS) recorded Receivables - Accured of $800,000 in Q4 2017.

Analysis

SELLAS Life Sciences (SLS) Receivables - Accured (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables - Accured (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn -
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn -
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 SELLAS Life Sciences 2.34 Bn 2.34 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 800,000.00
API Access

SELLAS Life Sciences Receivables - Accured API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-accured&ticker=SLS&period=max&api_key=YOUR_API_KEY